X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company’s lead product candidate LSTA1 (certepetide), the FDA has granted orphan drug designation for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents, and young adults.
Lead Product(s): Certepetide
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
LSTA1 (certepetide) is an investigational drug designed to activate a novel uptake pathway that allows co-administered anti-cancer drugs to penetrate solid tumors more effectively. It is being evaluated for the treatment of osteosarcoma.
Lead Product(s): Certepetide
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
LSTA1 (certepetide) is an investigational drug designed to activate a novel uptake pathway that allows co-administered anti-cancer drugs to penetrate solid tumors more effectively. It is being evaluated in phase 2 clinical trials for the treatment of glioblastoma multiforme.
Lead Product(s): Certepetide,Temozolomide
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
LSTA1 (certepetide) is an investigational drug designed to activate a novel uptake pathway that allows co-administered anti-cancer drugs to penetrate solid tumors more effectively. It is being evaluated for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): LSTA1,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate malignant glioma more effectively, which is investigated for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Certepetide,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate malignant glioma more effectively, which is investigated for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): LSTA1,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate malignant glioma more effectively.
Lead Product(s): LSTA1,Temozolomide
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
LSTA1 the lead product candidate from the CendR Platform™, has the potential to be combined with a myriad of chemo and immunotherapeutic agents that could become an integral part of a revised standard-of-care therapy for many difficult to treat cancers.
Lead Product(s): LSTA1,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Sydney
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
The merged company will operate as Lisata Therapeutics, Inc. and will focus primarily on advancing its CendR Platform™ technology product candidates in a range of oncology indications including CEND-1, in addition to Caladrius’ existing development programs.
Lead Product(s): LSTA1,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Lisata Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 15, 2022
Details:
Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study.
Lead Product(s): CEND-1,Atezolizumab,Gemcitabine
Therapeutic Area: Oncology Product Name: CEND-1
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
